However, the percentage of Nestin-positive tumor area markedly decreased in shICAM-1 tumor–bearing mice treated with bevacizumab (34.20 ± 3.66%, p < 0.001) or vehicle (24.10 ± 4.16 %, p < 0.001), compared to GSC11GFP generated tumor treated with bevacizumab respectively (Figure 4E). This evidence concerns the gene NES and neoplasm.